Months after the Niskayuna school district voted to change its school nickname, the town has approved a new logo.

AstraZeneca penned a discovery pact with China's CSPC Pharma. The FDA halted new trials that export American people's living cells to China.

AstraZeneca announced that it has entered into a strategic research collaboration with CSPC Pharmaceutical Group to accelerate the discovery and development of novel oral therapies using artificial ...

On June 13, 2025, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceuticals to advance AI-enabled drug discovery. This partnership aims to develop novel oral candidates ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

In a press release on June 13, 2025, AstraZeneca announced its entry into a strategic research collaboration with CSPC Pharmaceuticals Group, based in Shijiazhuang City, China (1). The two companies ...

Notably, CSPC Pharma chose to flag up the potential for a big pay-off just after it had reported disappointing quarterly earnings, with profits squeezed by price controls in China's national ...

On Thursday, HSBC (LON: HSBA) analysts upgraded CSPC Pharmaceutical (TADAWUL: 2070) Group Ltd. (1093:HK) (OTC: CHJTF) stock rating from Hold to Buy. The upgrade is accompanied by a new price target of ...

HSBC’s analysts see further upside potential for CSPC shares, supported by expectations of new drug launches and an accelerated pace of business development with larger income scales.